logo
Researchers quietly planned a test to dim sunlight. They wanted to ‘avoid scaring' the public.

Researchers quietly planned a test to dim sunlight. They wanted to ‘avoid scaring' the public.

Politico27-07-2025
They also offer a rare glimpse into the vast scope of research aimed at finding ways to counter the Earth's warming, work that has often occurred outside public view. Such research is drawing increased interest at a time when efforts to address the root cause of climate change — burning fossil fuels — are facing setbacks in the U.S. and Europe. But the notion of human tinkering with the weather and climate has drawn a political backlash and generated conspiracy theories, adding to the challenges of mounting even small-scale tests.
Last year's experiment, led by the University of Washington and intended to run for months, lasted about 20 minutes before being shut down by Alameda city officials who objected that nobody had told them about it beforehand.
That initial test was only meant to be a prequel. Even before it began, the researchers were talking with donors and consultants about conducting a 3,900-square mile cloud-creation test off the west coasts of North America, Chile or south-central Africa, according to more than 400 internal documents obtained by E&E News through an open records request to the University of Washington.
'At such scales, meaningful changes in clouds will be readily detectable from space,' said a 2023 research plan from the university's Marine Cloud Brightening Program. The massive experiment would have been contingent upon the successful completion of the thwarted pilot test on the carrier deck in Alameda, according to the plan. The records offer no indication of whether the researchers or their billionaire backers have since abandoned the larger project.
Before the setback in Alameda, the team had received some federal funding and hoped to gain access to government ships and planes, the documents show.
The university and its partners — a solar geoengineering research advocacy group called SilverLining and the scientific nonprofit SRI International — didn't respond to detailed questions about the status of the larger cloud experiment. But SilverLining's executive director, Kelly Wanser, said in an email that the Marine Cloud Brightening Program aimed to 'fill gaps in the information' needed to determine if the technologies are safe and effective.
In the initial experiment, the researchers appeared to have disregarded past lessons about building community support for studies related to altering the climate, and instead kept their plans from the public and lawmakers until the testing was underway, some solar geoengineering experts told E&E News. The experts also expressed surprise at the size of the planned second experiment.
'Alameda was a stepping stone to something much larger, and there wasn't any engagement with local communities,' said Sikina Jinnah, an environmental studies professor at the University of California in Santa Cruz. 'That's a serious misstep.'
In response to questions, University of Washington officials downplayed the magnitude of the proposed experiment and its potential to change weather patterns. Instead, they focused on the program's goal of showing that the instruments for making clouds could work in a real-world setting. They also pushed back on critics' assertions that they were operating secretively, noting that team members had previously disclosed the potential for open-ocean testing in scientific papers.
The program does not 'recommend, support or develop plans for the use of marine cloud brightening to alter weather or climate,' Sarah Doherty, an atmospheric and climate science professor at the university who leads the program, said in a statement to E&E News. She emphasized that the program remains focused on researching the technology, not deploying it. There are no 'plans for conducting large-scale studies that would alter weather or climate,' she added.
Growing calls for regulation
Solar geoengineering encompasses a suite of hypothetical technologies and processes for reducing global warming by reflecting sunlight away from the Earth that are largely unregulated at the federal level. The two most researched approaches include releasing sulfate particles in the stratosphere or spraying saltwater aerosols over the ocean.
But critics of the technologies warn that they could also disrupt weather patterns — potentially affecting farm yields, wildlife and people. Even if they succeed in cooling the climate, temperatures could spike upward if the processes are abruptly shut down before countries have transitioned away from burning planet-warming fossil fuels, an outcome described by experts as 'termination shock.'
As a result, even researching them is controversial — and conspiracy theories driven by weather tragedies have worsened the backlash.
Rep. Marjorie Taylor Greene (R-Ga.) has erroneously suggested that geoengineering is responsible for the deadly July 4 flood in Texas and introduced a bill to criminalize the technology. Retired Lt. Gen. Mike Flynn, a former national security adviser to President Donald Trump, has embraced similar untruths.
Meanwhile, more than 575 scientists have called for a ban on geoengineering development because it 'cannot be governed globally in a fair, inclusive, and effective manner.' And in Florida, Republican Gov. Ron DeSantis signed a law last month that bans the injection or release of chemicals into the atmosphere 'for the express purpose of affecting the temperature, weather, climate, or intensity of sunlight.'
Conspiracy theories involving the weather have reached enough of a pitch that EPA Administrator Lee Zeldin released a tranche of information this month debunking the decades-old claim that jet planes intentionally release dangerous chemicals in their exhaust to alter the weather or control people's minds.
The small Alameda experiment was one of several outdoor solar geoengineering studies that have been halted in recent years due to concerns that organizers had failed to consult with local communities. The city council voted to block the sprayer test in June 2024 after Mayor Marilyn Ezzy Ashcraft, a Democrat, complained that she had first learned about it by reading a New York Times article.
The Alameda officials' sharp reaction echoed responses to past blunders by other geoengineering researchers. An experiment in Sweden's Arctic region that sought to release reflective particles in the stratosphere was canceled in 2021 after Indigenous people and environmentalists accused Harvard University of sidelining them. The entire program, known as SCoPEx, was terminated last year.
'It's absolutely imperative to engage with both local communities and broader publics around not just the work that is being proposed or is being planned, but also the broader implications of that work,' said Jinnah, the UC Santa Cruz professor, who served on the advisory board for SCoPEx.
That view isn't universally shared in the solar geoengineering research community. Some scientists believe that the perils of climate change are too dire to not pursue the technology, which they say can be safely tested in well-designed experiments, such as the one in Alameda.
'If we really were serious about the idea that to do any controversial topic needs some kind of large-scale consensus before we can research the topic, I think that means we don't research topics,' David Keith, a geophysical sciences professor at the University of Chicago, said at a think tank discussion last month. Keith previously helped lead the canceled Harvard experiment.
Team sought U.S. ships, planes and funding
The trove of documents shows that officials with the Marine Cloud Brightening Program were in contact with officials from the National Oceanic and Atmospheric Administration and the consulting firm Accenture as the researchers prepared for the much larger ocean test — even before the small field test had begun on the retired aircraft carrier USS Hornet. They had hoped to gain access to U.S. government ships, planes and research funding for the major experiment at sea. (NOAA did not respond to a request for comment.)
After local backlash doomed the Alameda test, the team acknowledged that those federal resources were likely out of reach. The prospect of U.S. backing became more distant with the reelection of Trump, who opposes federal support for measures to limit global warming. (The White House didn't respond to a request for comment.)
The program's donors include cryptocurrency billionaire Chris Larsen, the philanthropist Rachel Pritzker and Chris Sacca, a venture capitalist who has appeared on Shark Tank and other TV shows. (Pritzker and Sacca didn't respond to requests for comment.)
Larsen said research of marine cloud brightening is needed due to questions about the effectiveness and impacts of the technology. 'At a time when scientists are facing political attacks and drastic funding cuts, we need to complement a rapid energy transition with more research into a broad range of potential climate solutions,' he wrote in an email to E&E News.
The 2023 research plan shows that the experiments in Alameda and at sea would have cost between $10 million and $20 million, with 'large uncertainties' due to operational or government funding challenges and the potential to expand the 'field studies to multiple geographic locations.'
They would require 'significant cash at the outset' and continued support over several years, the plan said. It was submitted as part of a funding request to the Quadrature Climate Foundation, a charity associated with the London-based hedge fund Quadrature Capital.
The Quadrature foundation told E&E News it had given nearly $11.9 million to SilverLining and $5 million to the University of Washington for research on solar geoengineering, which is also known as solar radiation management, or SRM.
'Public and philanthropic institutions have a role in developing the knowledge needed to assess approaches like SRM,' Greg De Temmerman, the foundation's chief science officer, said in a statement. The goal is to ensure that decisions about the potential use of the technologies 'are made responsibly, transparently, and in the public interest.'
'Avoid scaring them'
For more than a dozen years, the University of Washington has been studying marine cloud brightening to see if the potential cooling effects are worth the risks, the research team told Quadrature.
'The MCB Program was formed in 2012 and operated as a largely unfunded collaboration until 2019, when modest philanthropic funding supported the commencement of dedicated effort,' the plan said.
The source of the program's initial financial support isn't named in the document. But the timing coincides with the establishment of SilverLining, which is six years old.
SilverLining reported more than $3.6 million in revenues in 2023, the most recent year for which its tax filings are publicly available. The group does not disclose its full list of donors, although charities linked to former Democratic New York Gov. Eliot Spitzer and the late Gordon Moore, a co-founder of the chipmaker Intel, have reported six-figure contributions to the group. (The Bernard and Anne Spitzer Charitable Trust didn't respond to a request for comment.)
'The Moore Foundation is not involved in the Marine Cloud Brightening Program,' said Holly Potter, a spokesperson for the charity, adding that 'solar geoengineering research in not a focus of the foundation's work.'
The program pitched Quadrature and other donors on the idea that its need for private philanthropy was only temporary. Public support would eventually arrive for solar geoengineering research, the team argued.
In a 2021 update for supporters, the team said it had received $1 million over two years from NOAA and the Department of Energy for modeling studies and had begun work on the modified snow-making machine that the researchers would later test in Alameda. That technology is also being used in a field trial along the Great Barrier Reef that's funded in part by the Australian government.
At the same time, the donor report acknowledged the potential for 'public perception challenges' like those that would later short-circuit the Alameda field test. 'The MCB Program is well-positioned both in terms of its government ties, scientific analogues and careful positioning to move forward successfully, but this remains a risk.'
The plan for Alameda included elements to engage the public. The deck of the USS Hornet, which is now a naval museum, remained open to visitors.
But the team relied on museum staff to manage relations with Alameda leaders and carefully controlled the information it provided to the public, according to the documents provided by the University of Washington that included communications among the program leaders.
'We think it's safest to get air quality review help and are pursuing that in advance of engaging, but I'd avoid scaring them overly,' said an Aug. 23, 2023, text message before a meeting with Hornet officials. 'We want them to work largely on the assumption that things are a go.' No names were attached to the messages.
Then in November 2023, a climate solutions reporter from National Public Radio was planning to visit the headquarters of SRI for a story about the importance of aerosols research. A communications strategist who worked for SilverLining at the time emailed the team a clear directive: 'There will be no mention of the study taking place in Alameda,' wrote Jesus Chavez, the founder of the public relations firm Singularity Media, in bold, underlined text. (Chavez didn't respond to a request for comment.)
At the same time, the program was closely coordinating with government scientists, documents show.
The head of NOAA's chemical sciences division was one of three 'VIPs' who were scheduled to visit the headquarters of SRI for a demonstration of a cloud-making machine, according to a December 2023 email from Wanser of SilverLining. Other guests included a dean from the University of Washington and an official from the private investment office of billionaire philanthropist Bill Gates, a long-time supporter of geoengineering research. (Gates Ventures didn't respond to a request for comment.)
'The focus of this event is on the spray technology and the science driving its requirements, validation and possible uses,' Wanser wrote to the team.
The same month, the program detailed its progress toward the Alameda experiment in another donor report.
'The science plan for the study has been shared with our colleagues at NOAA and DOE,' said a draft of the report.
A Department of Energy spokesperson acknowledged funding University of Washington 'research on how ambient aerosols affect clouds,' but said the agency hadn't supported 'deliberate field deployment of aerosols into the environment.'
Mayor wondered 'where it's leading to'
On April 1, 2024, the day before the Alameda experiment was launched, the program and its consultants appeared to be laying the groundwork for additional geoengineering tests, which an adviser said would likely need the support of federal officials.
Leaders from SilverLining, SRI and Accenture were invited to attend the discussion 'to kick off the next phase of our work together' in the consulting firm's 33rd floor offices in Salesforce Tower, the tallest building in San Francisco, a calendar invitation shows. Officials from the University of Washington and NOAA were also given the option to join. That evening, the calendar notifications show, everyone was invited to a happy hour and dinner.
Accenture, SRI, the University of Washington and NOAA didn't directly respond to questions about the events. Wanser of SilverLining said in an email that the San Francisco meeting 'was completely separate' from the cloud brightening program, even though it included many of the same researchers.
The following afternoon, team members and Accenture executives planned to give a sprayer demonstration to Pritzker, an heir to the Hyatt Hotels fortune and board chair of the think tanks Third Way and the Breakthrough Institute, and Michael Brune, a former executive director of the Sierra Club, according to another scheduling document.
It was an important moment for the team. The same technology that was being tested on the aircraft carrier's deck would also be deployed in the much larger open-ocean experiment, the research plan shows.
'I was impressed with the team that was putting it together,' Brune said in an interview. He attended the demo as an adviser to Larson, the crypto entrepreneur who has donated to SilverLining via the Silicon Valley Community Foundation.
Brune, who lives in Alameda, said he wasn't aware of the larger experiment until E&E News contacted him. 'The engagement with leaders here in Alameda was subpar, and the controversy was pretty predictable,' he added.
In May 2024, city officials halted the experiment after complaining about the secrecy surrounding it. They also accused the organizers of violating the Hornet's lease, which was only intended to allow museum-related activities. (The Hornet didn't respond to a request for comment.)
At a city council meeting the following month, Mayor Ashcraft said she wanted 'a deeper understanding of the unintended consequences … not just of this small-scale experiment, but of the science, of this technology [and] where it's leading to.' Then she and the other four council members voted unanimously to block the program from resuming its experiment.
Using federal aircraft 'isn't going to happen'
Between April 2024 and the city council's vote that June, the research team scrambled to limit public backlash against the test. By then, the controversy had attracted national and local media attention.
The information request from E&E News sought roughly 14 months of text messages from or to Doherty and Robert Wood, another University of Washington researcher, that included or mentioned their collaborators at SilverLining or SRI. Some of the text messages that were shared by the university did not specify the sender, and Doherty and Wood did not respond to questions about them.
In one text message chain on May 15, 2024, one person suggested SilverLining would pay to keep the Hornet museum closed when the tests were running 'to give us some breathing space.'
The sender added, 'for risk management and the project [it's] an easy call, and we can cover it.'
But an unidentified second person responded that 'the community could actually find it additionally problematic that the project kept the Hornet shut down.'
The team members sent each other letters from people who supported the program, including one from science fiction writer Kim Stanley Robinson, whose 2020 novel Ministry of the Future featured a rogue nation that unilaterally implemented planetary-scale solar geoengineering.
'The truth is that in the coming decades we are going to have to cope with climate change in many ways involving both technologies and social decisions,' he wrote to the city council on May 29, 2024. The Alameda experiment 'has the advantage of exploring a mitigation method that is potentially very significant, while also being localized, modular, and reversible. These are qualities that aren't often attributed to geoengineering.'
After the council vote, SilverLining hired a new public relations firm, Berlin Rosen, to handle the media attention. It also discussed organizing local events to recruit potential allies, emails show.
Wanser, SilverLining's executive director, wrote in a June 6, 2024, email to the research team that the program was considering 'another run at a proposal to the city post-election, with, hopefully, a build up of local support and education in the interim.'
Ashcraft, the mayor, said in an email to E&E News that she is 'not aware of any additional outreach with the community' by the researchers, adding that they hadn't engaged with her or city staff since the vote.
Meanwhile, even before Trump returned to office, the team had begun acknowledging that its mistakes in Alameda had decreased the likelihood of gaining government support for solar geoengineering research. Access to federal aircraft 'isn't going to happen any time soon,' Doherty, the program director, wrote to Wanser and other team members on June 14, 2024.
The studies that the program is pursuing are scientifically sound and would be unlikely to alter weather patterns — even for the Puerto Rico-sized test, said Daniele Visioni, a professor of atmospheric sciences at Cornell University. Nearly 30 percent of the planet is already covered by clouds, he noted.
That doesn't mean the team was wise to closely guard its plans, said Visioni, who last year helped author ethical guidelines for solar geoengineering research.
'There's a difference between what they should have been required to do and what it would have been smart for them to do, from a transparent perspective, to gain the public's trust,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Molecular Testing in Dermatology: Who and When to Test
Molecular Testing in Dermatology: Who and When to Test

Medscape

time11 hours ago

  • Medscape

Molecular Testing in Dermatology: Who and When to Test

SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some appear similar clinically — and can also identify specific genetic mutations and other characteristics that can help select optimal treatments. At the Society for Pediatric Dermatology (SPD) 2025 Annual Meeting, Virginia Sybert, MD, clinical professor of medical genetics at the University of Washington, Seattle, discussed what dermatologists need to know when using molecular testing in clinical practice in general, not specifically in pediatrics. Who and When to Test Knowing who and when to test is the first consideration, she said. 'Is the test needed for a diagnosis, needed for treatment, needed for prognosis, or is it needed for reproductive counselling or management that can predict a patient's response to certain therapies?' For example, Sybert said, for an older adult patient with six café au lait spots, bilateral axillary freckling, a plexiform neurofibroma, and 27 neurofibromas, is molecular testing needed to diagnose neurofibromatosis? 'No, it's a clinical diagnosis, and molecular information is not going to change prognosis or change management, so you don't always need to do a molecular test,' she noted. Sybert also pointed out that the cost of molecular testing has dramatically decreased in the last decade, and it now costs less to do a whole genome panel than an MRI, which 'is something to keep in mind when it comes to testing.' Which Test to Use The second consideration is which test to use, as there are now several types to choose from, and clinicians must decide which one is most appropriate for the need at hand, Sybert continued. Current options include a single gene test, a panel with multiple genes, whole exome testing, whole genome testing, microarray, karyotype, and RNA sequencing. 'Going back to our patient with neurofibromatosis, if you wanted to do a molecular test, you might just do a single gene,' she said. 'But doing a single gene test requires that you know what the patient has and affirms that you are going in the right direction.' But for a patient with suspected ichthyosis, testing for a single gene would be inadequate, as it is a genetically and clinically heterogeneous group of disorders. Therefore, a panel composed of known genetic mutations associated with ichthyosis would be needed. Another decision is where to test, as laboratories may offer different options. For an ichthyosis panel, Sybert compared two panels from two labs. Both test for about 50 different genes, and while there is a lot of overlap, there are also genes that each one offers that the other does not. 'So, you would need to know which panel you want to use and which genes you want to test for,' she explained. 'And you also need to know how the testing is done. Are you looking for targeted gene testing, sequencing, or deletions or duplications? Are you looking for mosaicism?' Another factor that must be considered is insurance coverage, because testing is often not covered. 'We probably spend more time trying to get insurance to cover [testing] than we do seeing the patient,' Sybert emphasized. 'You have to write a letter explaining how it may change management, and that can be time-consuming and frustrating.' Interpretation of Results 'Third, is that you know how to interpret those results,' Sybert said, 'and then we have to figure out what to do with them.' Interpreting results entails looking for point mutations in targeted genes; rearrangement of a chromosome or gene so there is loss or gain of material; partial or whole deletion or duplication of a gene/chromosome; and expansion/repeat diseases. The presentation of results can be daunting. Compared with the straightforward results of a simple blood test like a complete blood count, genetic testing results can be several pages long. The lab will provide a summary and highlight genetic variants identified in the test. Then what? There are three basic types of genetic variants. The first is those considered benign or likely benign, which are considered harmless variants and not expected to affect a person's health, and are not included in the lab report. The next group are pathogenic or likely pathogenic, which are expected to change how a gene functions and may cause a genetic disease or health risk. The third, and most ambiguous, are the 'variants of uncertain significance (VUS).' There is not enough information about these variants to know if they are harmless or diagnostic of a genetic condition. 'Variants of unknown significance are going to be where most of your results will be,' she said. 'But the vast majority of variants do not cause disease. The more testing you do, the more variants of unknown significance you will find.' When trying to interpret them, clinicians can see if they have been reported in databases of normal populations and what the population is or if they have been reported in the literature. 'You can see if it has been predicted to be benign or pathogenic, or if they correlate with family history,' Sybert said. 'You may find that everyone in the family has this variant.' But over time, variants can either be upgraded or downgraded, as demonstrated by a 2018 study on the prevalence of variant reclassification after genetic testing for hereditary cancer, published in JAMA . Of 1.67 million hereditary cancer tests, 7.7% of the unique variants of uncertain significance were reclassified. Of those, 91.2% were eventually downgraded to 'benign' or 'likely benign,' while 8.7% were upgraded to 'pathogenic' or 'likely pathogenic.' The possibility that at some point, interpretation of a VUS result may change should be discussed with the patient and family. 'We must emphasize that it is incumbent on them to touch base with us every few years,' Sybert said. Sybert emphasized that dermatologists 'are not alone' in regard to making decisions about genetic testing and interpreting results, which can be daunting. She encouraged dermatologists to reach out to genetic clinics at their institution, genetic counselors, and geneticists.

Common sweetener could hold untapped potential to fight aggressive cancer, study finds
Common sweetener could hold untapped potential to fight aggressive cancer, study finds

Yahoo

timea day ago

  • Yahoo

Common sweetener could hold untapped potential to fight aggressive cancer, study finds

A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. Read On The Fox News App This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. Ancient 'Pharaoh's Curse' Fungus Shows Promise In Killing Cancer Cells "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. Click Here To Sign Up For Our Health Newsletter "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. For more Health articles, visit "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for article source: Common sweetener could hold untapped potential to fight aggressive cancer, study finds Solve the daily Crossword

Common sweetener could hold untapped potential to fight aggressive cancer, study finds
Common sweetener could hold untapped potential to fight aggressive cancer, study finds

Fox News

time2 days ago

  • Fox News

Common sweetener could hold untapped potential to fight aggressive cancer, study finds

A household sweetener could hold the potential to create an anti-cancer treatment. New research from Hiroshima University in Japan revealed that stevia leaf extract could help fight pancreatic cancer cells. The leaves of the stevia plant (Stevia rebaudiana) are used to make stevia extract, a naturally sweet substance commonly used as a sugar substitute. The study, published in the International Journal of Molecular Sciences, investigated the anti-cancer properties of stevia leaf extract when it is fermented with a certain strain of bacteria. In laboratory research, the fermented extract exhibited "significantly enhanced antioxidant activity and cytotoxicity" against pancreatic cancer cells, the researchers revealed. This led them to believe that this substance could serve as a "promising candidate for pancreatic cancer treatment." Paul E. Oberstein, M.D., medical oncologist and assistant director of the Pancreatic Cancer Center at NYU Langone Perlmutter Cancer Center, shared his thoughts in an interview with Fox News Digital. "This is an interesting study because it evaluated something derived from a natural plant (stevia) and showed that it may have utility in stopping cancer cells from growing in the laboratory," he said. "As the authors point out, the actual stevia plant does not seem to have any benefit for stopping cancer, so they had to use a chemical process to change the plant and make it stronger with a fermentation process." "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers." Oberstein recommended approaching this with caution, as it is unknown whether altering the plant will lead to side effects or toxicity. The study was not performed on humans, so there is "still a lot that's unknown about whether this will help patients," the oncologist added. As stevia extract alone does not have an impact on cancer cells, Oberstein said these findings most likely will not lead to any immediate changes in treatment plans. "The study suggests that if the stevia can be changed in the lab, it may have an impact, so hopefully they will further test this and determine whether this effect happens when tested in people and if it doesn't cause new side effects," he added. "I hope the researchers keep testing this in various formats and in people." Dr. Kristen Arnold, a surgical oncologist and pancreatic cancer specialist at the Orlando Health Cancer Institute, reacted to these study findings in a separate interview with Fox News Digital. "Pancreatic cancer is a very aggressive malignancy," she said. "And we know that even with the most aggressive of therapies, unfortunately, our outcomes are not good." "As a pancreatic cancer community, we spend a lot of time and there's a lot of ongoing effort into trying to find better modalities to treat this disease." Although more research is needed to confirm these preliminary findings, Arnold said she is encouraged by the study. "I think the data's very early to know if it's ultimately going to be a game-changer, but it's very exciting to know that we're finding some positive pre-clinical data," she said. "This is the process of how we discover new treatments – some of which turn out to be absolute game-changers and make dramatic changes in the lives of our patients." "Not all of it pans out, but it's a process of discovery," Arnold added. For those with pancreatic cancer, Arnold recommends seeking out appropriate clinical trial opportunities as new science develops. "The clinical trials are ultimately what determine how we treat patients on a day-to-day basis," she added. Fox News Digital reached out to the study authors for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store